A Pilot Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5, Alone or In Combination with Imatinib Mesylate or Sunitinib Malate In Subjects with Advanced Gastrointestinal Stromal Tumors

A Pilot Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5, Alone or In Combination with Imatinib Mesylate or Sunitinib Malate In Subjects with Advanced Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

Withdrawn

1

Age of Trial (yrs)

Gleevec-resistant

KIT/PDGFRA inhibitor + Death receptor activator

Activate death receptors + Block KIT

Specifically GIST and only GIST

RRC0708

Monica Davey

M_Davey@fccc.edu

215-728-5534

Oral

According to Melissa Spence at U. of Minn. the pharma has halted this study and is not going ahead.

This is a phase I trial with CS-1008, a monoclonal anitbody targeting death receptor 5. CS-1008 will be given either alone or in combination with imatinib (Gleevec) or sunitinib (Sutent).
The goal of any phase I trial is to determine if the drug or drug combination can safety be given to humans and to determine the maximum tolerated dose of the drug or drug combination and a drug schedule.
CS-1008 is designed to increase the number of tumor cells killed by activating a "cell death" pathway, the death receptor 5 (DR5) pathway. Giving this drug will imatinib or sunitinib might increase the effectiveness of these drugs.